Understanding how gene regulation contributes to leukemia and other diseases
Epigenetic mechanisms of regulation of histone lysine methyltransferases involved in leukemia
This research explores how specific enzymes that control our genes might lead to leukemia and other serious illnesses, aiming to find new ways to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11145916 on NIH RePORTER |
What this research studies
Our bodies have a complex system for turning genes on and off, which involves how our DNA is packaged inside cells. This packaging, called chromatin, can be modified by special enzymes that add or remove chemical tags on proteins called histones. When these enzymes, like Dot1L and MLL1, don't work correctly, it can lead to serious conditions such as leukemia. This project aims to understand exactly how these enzymes are regulated and how their malfunction contributes to disease. By uncovering these basic mechanisms, we hope to identify new targets for treatments for leukemia and other related illnesses, including African sleeping sickness.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients but aims to benefit individuals with leukemia, particularly those with specific genetic alterations involving MLL1 or Dot1L, and potentially those affected by African sleeping sickness.
Not a fit: Patients whose conditions are not related to the specific gene regulation mechanisms or enzymes (MLL1, Dot1L) being studied may not directly benefit from this particular research.
Why it matters
Potential benefit: Understanding these fundamental mechanisms could lead to the development of new drugs that specifically target these enzymes to treat leukemia and other diseases.
How similar studies have performed: Inhibition of Dot1L and MLL1 has shown promise as a therapeutic strategy in other studies, suggesting that targeting these enzymes is a valid approach.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Armache, Karim Jean — New York University School of Medicine
- Study coordinator: Armache, Karim Jean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.